ProShare Advisors LLC Buys Shares of 11,888 UroGen Pharma Ltd. (NASDAQ:URGN)

ProShare Advisors LLC purchased a new position in UroGen Pharma Ltd. (NASDAQ:URGN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,888 shares of the company’s stock, valued at approximately $199,000. ProShare Advisors LLC owned 0.05% of UroGen Pharma as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in URGN. China Universal Asset Management Co. Ltd. grew its position in UroGen Pharma by 65.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,903 shares of the company’s stock worth $89,000 after purchasing an additional 2,328 shares during the period. Rice Hall James & Associates LLC boosted its stake in shares of UroGen Pharma by 3.4% in the 2nd quarter. Rice Hall James & Associates LLC now owns 72,787 shares of the company’s stock worth $1,221,000 after buying an additional 2,381 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of UroGen Pharma by 3.7% in the 2nd quarter. ARK Investment Management LLC now owns 151,781 shares of the company’s stock worth $2,547,000 after buying an additional 5,452 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of UroGen Pharma by 37.2% in the second quarter. Rhumbline Advisers now owns 50,477 shares of the company’s stock worth $847,000 after acquiring an additional 13,681 shares during the period. Finally, Sierra Summit Advisors LLC purchased a new stake in UroGen Pharma during the fourth quarter valued at $218,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Trading Up 2.6 %

Shares of NASDAQ:URGN opened at $12.70 on Friday. UroGen Pharma Ltd. has a 12-month low of $10.60 and a 12-month high of $20.70. The company has a market cap of $297.87 million, a PE ratio of -3.74 and a beta of 1.11. The stock has a 50 day moving average of $14.04 and a 200 day moving average of $14.53. The company has a current ratio of 8.15, a quick ratio of 7.93 and a debt-to-equity ratio of 3.23.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to analyst estimates of $23.69 million. As a group, equities research analysts expect that UroGen Pharma Ltd. will post -3.49 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on URGN shares. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of UroGen Pharma in a research report on Thursday. LADENBURG THALM/SH SH boosted their target price on shares of UroGen Pharma from $48.00 to $53.50 and gave the company a “buy” rating in a research report on Friday, June 14th. Oppenheimer increased their price target on shares of UroGen Pharma from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, June 14th. Finally, Guggenheim initiated coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price objective for the company.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.